Press Releases :: Sonnet BioTherapeutics, Inc. (PURR)

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Trading on The Nasdaq Capital Market under the ticker symbol “PURR”

Full Press Release Here

Jul 24, 2024 8:30am EDT

Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study

Jun 20, 2024 8:30am EDT

Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds

Jun 13, 2024 8:00am EDT

Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain

May 28, 2024 8:00am EDT

Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting

May 22, 2024 8:33am EDT

Sonnet BioTherapeutics Announces Review of Strategic Alternatives

May 20, 2024 9:15am EDT

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target

May 14, 2024 4:15pm EDT

Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update

May 06, 2024 7:00am EDT

Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference

Mar 19, 2024 7:30am EDT

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

Mar 11, 2024 7:30am EDT

Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective

1
2
3
4
5
6
7
8
9
10
...13